Bristol-Myers Squibb Company (LON: 0R1F)

Market Cap	94.01B
Revenue (ttm)	35.39B
Net Income (ttm)	-5.42B
Shares Out	n/a
EPS (ttm)	-2.67
PE Ratio	n/a
Forward PE	n/a
Dividend	1.90 (2.61%)
Ex-Dividend Date	Jan 3, 2025

Volume	2,046
Average Volume	8,137
Open	72.71
Previous Close	72.70
Day's Range	72.70 - 75.64
52-Week Range	57.97 - 81.40
Beta	0.44
RSI	52.43
Earnings Date	Feb 6, 2025

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1887
• Employees: 34,100
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R1F

Financial Performance

In 2023, Bristol-Myers Squibb Company's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.

Financial numbers in USD